Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
The PRECISION is a proof-of-concept, phase II randomized clinical trial aiming to evaluate
the efficacy and safety of anakinra in patients with Post-Acute COVID Syndrome (PACS) of the
pro-inflammatory respiratory phenotype. Improvement is measured by a composite endpoint,
namely, the "Score of PACS progression reversal"